September 19, 2017 1:09 PM ET


Company Overview of S1 Biopharma Inc

Company Overview

S1 Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for sexual dysfunction. The company has a portfolio of four clinical and pre-clinical stage drug candidates. Its principal product candidate is Lorexys, a proprietary fixed-dose combination therapy for the treatment of female hypoactive sexual desire disorder (HSDD). The company also develops Orexa for the treatment of male HSDD. In addition, it develops two pre-clinical candidates, including S1B-307, a peptide for the treatment of female sexual arousal disorder and female orgasmic disorder; and S1B-3006, a proprietary second-generation agent combining active compound...

7 World Trade Center

250 Greenwich Street

46th Floor

New York City, NY 10007

United States

Founded in 2010

4 Employees



Key Executives for S1 Biopharma Inc

Chairman, Chief Executive Officer and President
Age: 42
Chief Financial Officer
Age: 41
Chief Medical Officer and Member of Advisory Board
Age: 74
Compensation as of Fiscal Year 2017.

S1 Biopharma Inc Key Developments

S1 Biopharma, Inc. and CKD Pharmaceuticals Enter into Commercialization Agreement for Lorexys

S1 Biopharma Inc. and CKD Pharmaceuticals announced that they have entered into a commercialization agreement for Lorexys™, S1 Biopharma's investigational therapy currently positioned to advance to a Phase 2b clinical trial for treatment of HSDD in women. Under the terms of the agreement, CKD acquires rights to commercialize Lorexys throughout South Korea. The terms include an upfront payment to S1 Biopharma and additional payments based on milestones as well as royalties on future product sales. CKD also has right of first refusal for commercialization agreements related to additional potential indications for Lorexys.

S1 Biopharma Inc Presents at Sofinnova Japan Biopharma Partnering Conference 2015, Oct-27-2015 05:30 PM

S1 Biopharma Inc Presents at Sofinnova Japan Biopharma Partnering Conference 2015, Oct-27-2015 05:30 PM. Venue: Conrad Hotel, 1-9-1, Higashi-Shinbashi, Minato-Ku, Tokyo, 105 7337, Japan.

S1 Biopharma Inc Presents at BIO-Europe 2015, Nov-03-2015 11:15 AM

S1 Biopharma Inc Presents at BIO-Europe 2015, Nov-03-2015 11:15 AM. Venue: Munich, Germany.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact S1 Biopharma Inc, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at